Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
8.74 USD | -5.72% |
|
-3.03% | -52.80% |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-52.80% | 212M | - | ||
+0.83% | 207B | B | ||
+3.60% | 181B | B- | ||
+29.91% | 155B | B- | ||
+32.17% | 112B | A- | ||
+1.98% | 64.42B | A- | ||
+19.23% | 54.38B | B+ | ||
-1.86% | 47.43B | B+ | ||
-9.34% | 37.17B | A | ||
-1.76% | 34.81B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
- Stock Market
- Equities
- CLXT Stock
- CLXT Stock
- Ratings Cibus, Inc.